Sakar Healthcare Ltd (SAKAR) AI Stock Analysis

• Market Cap: ₹8.34B
• Dividend Yield: N/A
• Average Volume (3M): 19.08K
• Price to Earnings (P/E): 43.0
• Beta (1Y): 0.50
• Revenue Growth: 24.20%
• EPS Growth: 55.01%
• Country: IN
• Employees: 325
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.04
• Shares Outstanding: 21,949,910
• 10 Day Avg. Volume: 18,950
• 30 Day Avg. Volume: 19,083
• PEG Ratio: 0.71
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 2.88
• P/FCF Ratio: -37.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ₹421.00 ▲(3.55% Upside)

Sakar Healthcare Ltd's overall stock score is driven by strong financial performance and positive technical indicators. However, the high P/E ratio suggests potential overvaluation, and the lack of dividend yield is a concern. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth and operational efficiency indicate a robust business model and market demand, supporting long-term expansion.

Debt Management

Improved debt management enhances financial stability and reduces risk, providing more flexibility for strategic investments.

Operational Efficiency

Improved EBIT margins reflect better cost management and operational efficiencies, contributing to sustainable profitability.

Negative Factors

Free Cash Flow Challenges

Negative free cash flow suggests difficulties in covering capital expenditures, potentially limiting growth and investment capabilities.

Gross Profit Margin Decline

A significant drop in gross profit margin indicates rising costs or pricing pressures, which could impact future profitability.

Net Profit Margin Concerns

Lower net profit margins suggest higher operating costs, which may affect the company's ability to generate sustainable profits.

Sakar Healthcare Ltd Business Overview & Revenue Model

Company Description

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

How the Company Makes Money

Sakar Healthcare Ltd generates revenue through multiple streams, primarily by selling pharmaceutical products, medical devices, and healthcare services. The company enters into strategic partnerships with healthcare providers, hospitals, and pharmacies to ensure wide distribution of its products. Additionally, SAKAR may engage in contract manufacturing for other companies, producing goods under specific agreements, which provides a steady revenue source. The company also invests in research and development to innovate new products, allowing it to capture emerging market demands and thus diversify its revenue base.

Sakar Healthcare Ltd Financial Statement Overview

Summary

Sakar Healthcare Ltd shows strong revenue growth and improving operational efficiency, with increasing EBIT margins. The balance sheet indicates an improving debt position and stable equity support. However, challenges in maintaining consistent profitability and managing cash flow effectively remain.

Income Statement

Sakar Healthcare Ltd has demonstrated a consistent increase in revenue over the years, with a notable revenue growth rate of 15.2% in 2025 compared to 2024, and 15.6% from 2024 to 2023. The Gross Profit Margin has been fluctuating but remained strong, standing at 24.1% for 2025. However, the Net Profit Margin has been lower at 9.9% for 2025, indicating higher operating costs or expenses. The EBIT margin improved to 16.2% in 2025 from 12.9% in 2024, showing operational efficiency. Nonetheless, the drop in Gross Profit Margin from 45.3% in 2024 to 24.1% in 2025 is a concern.

Balance Sheet

The company's Debt-to-Equity ratio has improved, decreasing from 0.30 in 2024 to 0.26 in 2025, indicating a reduction in leverage. The Return on Equity (ROE) has been stable, with 6.1% in 2025, showcasing moderate profitability relative to equity. The Equity Ratio stood at 68.8% in 2025, reflecting a strong equity position. Despite the positive trends, the ratio of Total Debt to Stockholders' Equity remains notable, requiring careful monitoring.

Cash Flow

The Free Cash Flow has been negative but shows signs of improvement, with a 61.4% increase in 2025 compared to 2024. The Operating Cash Flow to Net Income ratio was strong at 1.07 in 2025, indicating that the company is efficiently converting its net income into cash. However, the Free Cash Flow to Net Income ratio remains negative, suggesting challenges in covering capital expenditures solely through operational earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.89B	1.78B	1.54B	1.33B	1.28B	947.39M
Gross Profit	680.80M	427.91M	699.59M	598.12M	534.12M	432.46M
EBITDA	528.86M	509.44M	393.27M	378.12M	315.72M	237.73M
Net Income	197.61M	175.02M	116.71M	127.59M	152.43M	106.83M
Balance Sheet
Total Assets	0.00	4.15B	3.89B	3.36B	2.68B	1.78B
Cash, Cash Equivalents and Short-Term Investments	3.09M	3.09M	4.66M	35.23M	71.36M	824.65K
Total Debt	0.00	749.55M	793.52M	1.19B	928.62M	425.97M
Total Liabilities	-2.85B	1.30B	1.26B	1.63B	1.40B	793.40M
Stockholders Equity	2.85B	2.85B	2.62B	1.73B	1.27B	984.52M
Cash Flow
Free Cash Flow	0.00	-135.52M	-350.93M	-468.81M	-618.33M	-209.69M
Operating Cash Flow	0.00	187.31M	244.67M	353.14M	356.99M	145.77M
Investing Cash Flow	0.00	-307.09M	-515.39M	-743.77M	-903.72M	-468.33M
Financing Cash Flow	0.00	-34.79M	274.45M	410.96M	320.33M	320.33M

Sakar Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 406.55
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Neutral. The current price of 406.55 is below the 20-day moving average (MA) of 411.67, above the 50-day MA of 395.38, and above the 200-day MA of 342.30, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 8.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SAKAR.

Sakar Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹9.72B	13.81	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.40B	2.57	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.34B	43.00	―	―	24.20%	55.01%
KILITCH	57 Neutral	₹5.85B	19.95	―	―	32.95%	67.39%
MEDICAMEQ	57 Neutral	₹5.29B	47.58	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹4.09B	-1.13	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sakar Healthcare Ltd Corporate Events

Sakar Healthcare to Supply Imatinib for Accord Healthcare’s EU Market After EMA Approval

Sakar Healthcare Ltd announced that its oncology manufacturing site has been approved as a production source for Accord Healthcare UK’s Imatinib Accord 100 mg and 400 mg film-coated tablets for the European Union market, following an EU variation approval by the European Medicines Agency. This marks the first of nine oncology products that Accord plans to transfer to Sakar, positioning the Indian company as a key supplier for Accord’s European oncology portfolio, and is expected to boost Sakar’s top-line sales and improve capacity utilisation while enabling it to prepare for supplying a broader range of approved products overseas.

Sakar Healthcare Schedules Investor Conference Call for Q2 & H1 FY26 Results

Sakar Healthcare Ltd has announced a scheduled conference call for analysts and investors to discuss their Q2 and H1 FY26 results. This call, set for November 11, 2025, aims to provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ understanding of its market positioning and operational strategies.

Sakar Healthcare Expands Oncology Product Reach with New Authorizations

Sakar Healthcare Ltd has announced the acquisition of nine new Marketing Authorizations for its oncology products, bringing the total to eleven across the European Union and emerging markets. This expansion allows Sakar to export a diverse range of cancer treatment products, enhancing its market presence and potentially increasing its export volume in these regions.